← back to search

Bo Liu

Chengdu Fifth People's Hospital · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Ferroptosis and cancer prognosis, Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research, and Effects of Radiation Exposure.
h-index
33
citations
4,124
works
243
NIH funding
primary concept
Medicine
email

Recent publications

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
New England Journal of Medicine 2025cited by 72position: middledoi
Noninvasively Real‐Time Monitoring In‐Vivo Immune Cell and Tumor Cell Interaction by NIR‐II Nanosensor
Advanced Materials 2025cited by 17position: middledoi
Camouflaged Nanozymes with Oxidation‐Promoting Activities Triggering Ferroptosis for Radio‐Immunotherapy
Advanced Science 2025cited by 16position: middledoi
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities
Journal of Hematology & Oncology 2025cited by 13position: lastdoi
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.
Journal of Clinical Oncology 2025cited by 8position: middledoi
Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.
Journal of Clinical Oncology 2025cited by 1position: middledoi
Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)
Cancer Communications 2025cited by 0position: middledoi
Abstract CT038: Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study
Cancer Research 2024cited by 18position: middledoi
A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.
Journal of Clinical Oncology 2023cited by 2position: middledoi
Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.
Journal of Clinical Oncology 2023cited by 1position: middledoi
Physical illness comorbidity and its influencing factors among persons with severe mental illness in Rural China
Asian Journal of Psychiatry 2022cited by 9position: middledoi
Where are we and where to go for supportive cancer care in China? A national survey of patients and healthcare providers
Research Square 2021cited by 1position: middledoi
Construction of lncRNA-related ceRNA regulatory network in diabetic subdermal endothelial cells
Figshare 2021cited by 0position: lastdoi
Automatic soil desiccation crack recognition using deep learning
Géotechnique 2020cited by 80position: middledoi
PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Clinical Cancer Research 2019cited by 77position: firstdoi
Duration of untreated psychosis (DUP) and outcome of people with schizophrenia in rural China: 14-year follow-up study
Psychiatry Research 2018cited by 42position: middledoi
Epidemiological comparison of adult talus fractures between East China and West China from 2010 to 2011
Zhonghua chuangshang guke zazhi 2018cited by 2position: middledoi
Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Clinical Cancer Research 2017cited by 108position: middledoi

Grants

NSF-BSF: Cytoskeletal Motor Assemblies for Plant Cytokinesis
NSF2416267$1,269,9932024–2028PIRePORTER
Collaborative Research: Molecular mechanisms governing the cytoskeleton-mediated motility and distribution of peroxisomes and mitochondria in plants
NSF2148207$981,3022022–2027PIRePORTER
Regulation of spindle microtubule organization in plants
NSF1920358$1,078,1842019–2023PIRePORTER
COLLABORATIVE RESEARCH: Establishing the microtubule-actin crosstalk in the preprophase band by the rice kinesin OsKCH2
NSF1616076$489,5752016–2019PIRePORTER
CyberSEES:Type2:Collaborative Research: SmartFarm - Research and Education for Sustainable Agriculture Practices
NSF1539570$150,0002015–2019PIRePORTER
Assembling the Phragmoplast Microtubule Array
NSF1412509$630,4902014–2018PIRePORTER
Microtubule Organization in Plant Cytokinesis
NSF1243959$200,0002013–2015PIRePORTER
Microtubule Organization by Kinesin-12 in the Phragmoplast
NSF0920454$608,2522009–2013PIRePORTER
Septum Formation in the Absence of the Septation Initiation Network in Aspergillus Nidulans
NSF0615892$518,2232006–2010PIRePORTER
Regulation of Cytokinesis by Microtubules in Aspergillus Nidulans
NSF0235364$276,0002003–2006PIRePORTER
RUI: Clustered Computer Network Control, Scheduling, and Management
NSF9504137$104,9811995–1998PIRePORTER

Frequent collaborators

Yumin Zhao · University of Alabama at Birmingham2 papers (2025–2025) · 2 papers (2017–2019)Wenhui Wu · Guangzhou University of Chinese Medicine2 papers (2017–2019)Likun Li · Nanjing Agricultural University2 papers (2017–2019)Takahiro Kamio · Daiichi Sankyo (United States)2 papers (2025–2025)Fabricio Souza · Daiichi Sankyo (United States)2 papers (2025–2025)Mahmut Gümüş · Istanbul Medeniyet University2 papers (2025–2025)Bradley M. Broom · The University of Texas MD Anderson Cancer Center2 papers (2017–2019)Kohei Shitara · Kindai University2 papers (2025–2025)Mudan Yang · Ningbo University2 papers (2023–2025) · 2 papers (2018–2022)Dimitrios Korentzelos · University of Pittsburgh Medical Center2 papers (2017–2019)Patricia Troncoso · The University of Texas MD Anderson Cancer Center2 papers (2017–2019)Lorenzo Fornaro · Novartis (Switzerland)2 papers (2025–2025)Timothy C. Thompson · The University of Texas MD Anderson Cancer Center2 papers (2017–2019)Sara Lonardi · Istituto Oncologico Veneto2 papers (2025–2025)Clélia Coutzac · Université Claude Bernard Lyon 12 papers (2025–2025)Paul G. Corn · The University of Texas MD Anderson Cancer Center2 papers (2017–2019)Jeroen Dekervel · KU Leuven2 papers (2025–2025)Wasat Mansoor · Manchester Academic Health Science Centre2 papers (2025–2025)